{"url":"https://newsforagent.com/news/2026-10-30/omniab-raises-2026-revenue-outlook","markdown_url":"https://newsforagent.com/news/2026-10-30/omniab-raises-2026-revenue-outlook.md","title":"OmniAb Raises 2026 Revenue Outlook","headline":"OmniAb Lifts 2026 Revenue Guidance to $35–$39 Million as Q3 Revenue Reaches $4.0 Million","description":"OmniAb raised its 2026 revenue guidance to $35–$39 million after third-quarter revenue of $4.0 million and signed an Eli Lilly ion channel collaboration.","section":"Earnings & Results","published_at":"2026-10-30T12:14:50+00:00","modified_at":"2026-10-30T12:14:50+00:00","author":"News Desk","key_takeaways":["OmniAb reported third-quarter 2026 revenue of $4.0 million, up from $2.2 million a year earlier.","OmniAb raised its full-year 2026 revenue guidance to $35 million–$39 million from $32 million–$36 million.","OmniAb entered a global collaboration and license agreement with Eli Lilly for an undisclosed ion channel program, with up to $370 million in milestones."],"companies":[{"name":"OmniAb","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00006cn/omniab","website":"http://www.omniab.com"},{"name":"Eli Lilly","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00000ap/eli-lilly","website":"https://www.lilly.com"}],"source":{"publisher":"TradingView","title":"OmniAb Raises 2026 Revenue Outlook After Third-Quarter Revenue Grows to $4.0 Million","url":"https://www.tradingview.com/news/tradingview:b58981bd663f1:0-omniab-raises-2026-revenue-outlook-after-third-quarter-revenue-grows-to-4-0-million/"},"other_sources":[],"tags":["Earnings & Results","OmniAb","Eli Lilly"],"body_markdown":"[OmniAb](https://akta.pro/company-profiles/00006cn/omniab) reported third-quarter 2026 revenue of $4.0 million, up from $2.2 million a year earlier, and raised its full-year revenue guidance to $35 million–$39 million from $32 million–$36 million. The company also entered a global collaboration and license agreement with Eli Lilly for an undisclosed ion channel program, [TradingView](https://www.tradingview.com/news/tradingview:b58981bd663f1:0-omniab-raises-2026-revenue-outlook-after-third-quarter-revenue-grows-to-4-0-million/) reported on October 30, 2026.\n\n## OmniAb's Third-Quarter Results and Lilly Ion Channel Deal\n\nOmniAb, based in Emeryville, licenses transgenic antibody discovery platforms such as OmniRat, OmniMouse, OmniChicken, OmniTaur and OmniUltra, together with xPloration single B-cell screening and Ab Initio antigen design, to pharmaceutical and biotechnology partners.\n\nThe third-quarter net loss was $15.7 million, or $0.12 per share, compared with $16.5 million, or $0.14 per share, a year earlier. Nine-month revenue rose to $31.8 million from $10.3 million, driven largely by milestone revenue, while the nine-month net loss narrowed to $29.3 million from $50.6 million. Cash, cash equivalents and short-term investments totaled $64.2 million at September 30, 2026.\n\nThe Eli Lilly agreement includes an upfront payment, eligibility for up to $370 million in research, development and commercial milestones, and tiered royalties. [Eli Lilly](https://akta.pro/company-profiles/00000ap/eli-lilly) is expanding into neurosciences after its obesity drug success, with CEO Dave Ricks citing the Centessa acquisition as opening sleep-wake disorder opportunities, The Times of India reported on October 29, 2026.\n\nAs of September 30, OmniAb had 111 active partners and 433 active programs, including 34 OmniAb-derived clinical and commercial programs. The company made its xPloration single B-cell screening platform available for purchase by all customers beginning in October and expects platform revenue to double in 2027 and double again in 2028. OmniAb also introduced OmniTides, a peptide discovery offering built on its OmniUltra transgenic chicken platform.\n\n## OmniAb's Cash Position and Partner Counts\n\nAccording to akta.pro [company records](https://akta.pro/company-data), OmniAb completed a $30 million private placement of 21,254,106 shares at $1.40 per share in August 2025, with closing around August 26, 2025, to fund general corporate purposes and extend the cash runway to approximately 20 months. The same records show 107 active partners and 409 active programs at the end of the first quarter of 2026, including 32 OmniAb-derived programs in clinical development or being commercialized.\n\n## OmniAb's Path to the Lilly Collaboration\n\nAt a conference in October 2026, OmniAb's CFO outlined its antibody-discovery licensing platform, citing 110 partners with 425 active programs and over $3 billion in potential milestones, MarketBeat reported. The company said then that it expected 2025 revenue of $32 million–$36 million and xPloration sales of $2 million–$3 million, with sales projected to double in 2027 and 2028.\n\nOmniAb launched OmniUltra in December 2025, a transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework, extending the platform into peptide therapeutics and modalities including bispecifics, CAR-T, radioligands and picobodies, according to akta.pro company records.\n\n## OmniAb's Year-End Cash Guidance\n\nOmniAb expects year-end cash and cash equivalents of $53 million–$57 million, up from its prior forecast of $49 million–$53 million.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}